Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have gained prominence as a therapeutic option in HF, demonstrating cardiovascular benefits including reduced hospitalizations and mortality. This evidence concerns the gene SLC5A2 and hydrops fetalis.